LP
PYXS icon

Longaeva Partners’s Pyxis Oncology PYXS Stock Holding History

Longaeva Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
353,582
-149,632
-30% -$286K 0.02% 294
2026
Q1 		$735K Hold
503,214
– – 0.03% 179
2025
Q4 		$579K Hold
503,214
– – 0.05% 109
2025
Q3 		$1.12M Buy
+503,214
New +$725K 0.16% 59

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Longaeva Partners's PYXS Position: Q2 2026 in Review

Longaeva Partners reduced its Pyxis Oncology (PYXS) stake by 30% in Q2 2026, selling an estimated $286K and leaving 353,582 shares worth $1.06M. The position accounts for 0.02% of the portfolio, ranked #294.

Longaeva Partners first reported a position in PYXS in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.12M in Q3 2025. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Longaeva Partners held 353,582 shares of Pyxis Oncology worth $1.06M as of Q2 2026.
  • Longaeva Partners sold 149,632 Pyxis Oncology shares in Q2 2026, an estimated $286K.
  • Pyxis Oncology made up 0.02% of Longaeva Partners's portfolio in Q2 2026, its #294 holding.
  • Longaeva Partners first reported a position in Pyxis Oncology in Q3 2025 and has held it in 4 quarters since.
  • Longaeva Partners's Pyxis Oncology position peaked at $1.12M in Q3 2025.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.